| Budget Amount *help |
¥19,760,000 (Direct Cost: ¥15,200,000、Indirect Cost: ¥4,560,000)
Fiscal Year 2010: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2009: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2008: ¥11,960,000 (Direct Cost: ¥9,200,000、Indirect Cost: ¥2,760,000)
|
|---|
| Research Abstract |
Seasonal allergic rhinitis caused by Japanese cedar (SAR-JC) is the most common allergic disease in Japan. The results of our recent study showed that about 30% of Japanese individuals develop allergic symptoms during JC pollination season. Allergen-specific immunotherapy (SIT) is the only available treatment that can provide long-term remission after discontinuation of treatment. Sublingual immunotherapy (SLIT), oral administration of the allergen, was introduced as a safety method. We found that apolipoprotein A-IV (apoA-IV) were significantly increased in SLIT-treated patients. The serum levels of apoA-IV correlated with the clinical effect. The amount of histamine released from the basophils in vitro was greatly reduced after the addition of recombinant apoA-IV in the medium. Our genetic studies found the association of polymorphisms of IL-33, DAF and Filaggrin with SAR-JC. They are possible therapeutic targets for SAR-JC.
|
